By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 139.31 |
Change Today | $ -1.35 |
% Change | -0.96 % |
52 Week High | $195.81 |
52 Week Low | $118.84 |
Volume | 1,102,769 |
Shares Issued | 145.80m |
Market Cap | $20,311m |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 5 |
Neutral | 21 |
Sell | 0 |
Strong Sell | 0 |
Total | 33 |
Time | Volume / Share Price |
16:00 | 100 @ $139.25 |
15:59 | 113 @ $139.25 |
15:59 | 100 @ $139.26 |
15:59 | 200 @ $139.30 |
15:59 | 600 @ $139.30 |
You are here: research